Citation Impact
6 from Science/Nature 53 standout
Citing Papers
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of Janet E. Murphy being referenced
Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.
2018
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
2017
Author Peers
| Author | Oncology | PRM | Cancer Research | Surgery | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Janet E. Murphy | 997 | 446 | 282 | 447 | 57 | 1.3k | |
| Erdinç Şahin Çonkur | 1 | 6 | 13 | 404 | |||
| Geng-Sun Qian | 452 | 53 | 409 | 56 | 8 | 1.8k | |
| D. Bakker | 4 | 21 | 255 | 20 | 673 | ||
| Steven N. Frank | 11 | 4 | 2 | 2 | 23 | 1.6k | |
| Malgorzata Harasymczuk | 454 | 79 | 171 | 36 | 16 | 1.1k |
All Works
Loading papers...